The result showed that in patients with NSCLC, FOXF2 mRNA level was an independent prediction factor for survival and the FOXF2low patients had a shorter survival time than the FOXF2high patients (HR = 2.384, 95% CI = 1.241–4.577; P = 0.009) especially in stage I NSCLC patients (HR = 4.367, 95% CI =1.599–11.925; P = 0.004) (Table 3, Figure 3). This evidence concerns the gene FOXF2 and non-small cell lung carcinoma.